< Back to previous page
Project
First-line chemoimmunotherapy using Wilms' tumor protein 1 (WT1)-targeted dendritic cell vaccinations for resectable malignant pleural mesothelioma.
The steadily increasing incidence of malignant pleural mesothelioma (MPM) along with the limited efficacy of the currently available treatment options for MPM prompts a search for new, more effective therapeutic modalities and strategies. Dendritic cells (DCs), the immune system's quintessential antigen-presenting cells, are a promising armament for immunotherapy of MPM. In this ph ase 1/11 clinical study, DCs loaded with the mesotheliomaassociated tumor antigen Wilms' tumor 1 protein (WT1) will be used in conjunction with conventional chemotherapy for the frontline treatment of resectabie MPM. The primaryobjective of th is project is to provide the first-in-human experimental demonstration that the combination of chemotherapy with WT1-targeted DC therapy enables the induction of both systemic and in situ mesothelioma-specific immune responses in patients with MPM.
Date:1 Jan 2013 → 31 Dec 2015
Keywords:MESOTHELIOMA, IMMUNOTHERAPY, DENDRITIC CELLS
Disciplines:Systems biology, Hematology, Laboratory medicine, Morphological sciences, Oncology